Europe Blood Brain Barrier Technologies Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (Bispecific Antibody RMT Approach, Trojan Horse Approach, Increasing Permeability, Passive Diffusion, and Other Non-Invasive BBB Technologies) and Application (Alzheimer’s Disease, Epilepsy, Parkinson’s Disease, Multiple Sclerosis, Hunter’s Syndrome, Brain Cancer, and Others)
Market Introduction
The Europe blood brain barrier technologies consists of Germany, UK, France, Italy, Spain, and the rest of Europe. In 2021, Germany held the largest share in the market. Germany is much ahead in terms of the healthcare industry. It has the presence of market leaders from across the world. Also, there are well-established players across the country that is contributing to the overall healthcare industry, including diagnostics and treatment of neurological diseases. The blood brain barrier technologies industry is a lucrative one in Germany which is driven by the factors such as the growing prevalence of neurological diseases such as meningitis, multiple sclerosis, Parkinson’s disease, and encephalitis. For instance, according to Globocan, in 2020, the number of new cases of brain, central nervous system cancer was 7697. Similarly, according to a data published in NCBI in 2017, the prevalence of brain associated aneurysm in Germany was around 11.3 per 100,000 persons in 2011. Additionally, in 2013, the prevalence reached to 22.1 per 100,000 persons. Such increasing prevalence of brain aneurysm is projected to drive the Germany brain aneurysm market during 2020-2027. In addition, according to Alzheimer Europe, in 2019, total 1585166 patients of Alzheimer were present in Germany and the overall numbers of people with dementia will rise from 1,585,166 in 2018 to 2,748,178 in 2050. Similarly, as a percentage of the overall population, people with dementia will represent 3.43% in 2050 compared to 1.91% in 2018.
The European economy is severely affected due to the exponential growth of COVID-19 cases in the region. Spain, Italy, Germany, France, and the UK are among the most affected European countries. In addition, new evidence has backed up a year-old theory that the Covid-19 infection causes neurological problems. This viewpoint initially developed in the summer of last year, during the pandemic's first wave. According to a preliminary (yet to be peer-reviewed) research by four Imperial College London academics, it is now considerably proven. Jiabin Tang, Shivani Patel, Steve Gentleman, and Paul M Matthew wrote the preprint, which indicates a "potential route" for the virus to enter the nervous system. The blood-brain barrier is a semi-permeable membrane of endothelial cells that protects the brain from the rest of the body. Monocytes, a kind of white blood cell, are activated as part of the body's defense mechanism when SARS-CoV-2 enters the bloodstream. To allow monocytes to cross the BBB, a complicated mechanism is activated. According to the article, "this facilitates the entry of infected and activated monocytes into the central nervous system, allowing the SARS-CoV-2 virus to pass through the loosened BBB.
Get more information on this report : 
Market Overview and Dynamics
The blood brain barrier technologies market in Europe is expected to grow from US$ 319.97 million in 2021 to US$ 1,548.76 million by 2028; it is estimated to grow at a CAGR of 25.3% from 2021 to 2028. Nanomedicine is a rapidly developing field with nanoparticles or nanostructures for medical applications, particularly in the underdeveloped area of drug delivery to the brain. Great expectations are placed on the ability of multifunctional nanoparticles (NPs) to cross the blood-brain barrier. Recent advances in nanotechnology allow otherwise poorly distributed drugs in the brain to be packaged into nanoparticles with brain-targeting properties. These targeted carrier systems enhance the delivery of drugs by entrapping or encapsulating the drug in the particle with a targeting peptide/ligand on its surface that results in BBB targeting. These carrier systems cross the BBB using transcellular pathways such as receptor-mediated endocytosis. A significant advantage of solid lipid nanoparticles is that their high lipid solubility physically stabilizes the nanoparticles, which increases the carrying capacity of the drug and results in a controlled release rate of the drug. Although lipid-based nanoparticles and formulations have a prolonged systemic circulation time and increased tumor retention due to increased permeation and retention, their most important limiting factor is rapid clearance from the bloodstream through the reticuloendothelial system. Several groups are working to improve targeting to the brain by mounting nanoparticles with ligands, which are substrates for BBB uptake transporters, facilitating transit to the brain. As this technology advances, this system can effectively deliver a variety of therapeutic agents with a favorable toxicity profile. Thus, the use of nanoparticles for brain drug delivery is expected to be the trend during the forecast period
Key Market Segments
In terms of technology, the increasing permeability segment accounted for the largest share of the Europe blood brain barrier technologies market in 2021. In terms of application, the parkinson’s disease segment accounted for the largest share of the Europe blood brain barrier technologies market in 2021.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the blood brain barrier technologies market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Teva Pharmaceutical Industries Ltd.; F. Hoffmann-La Roche Ltd.; Eli Lilly and Company; Bristol-Myers Squibb Company; Pfizer, Inc.; Johnson & Johnson Services, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Abliva AB.; and Bioasis Technologies, Inc. among others.
Reasons to buy report
- To understand the Europe blood brain barrier technologies market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe blood brain barrier technologies market
- Efficiently plan M&A and partnership deals in Europe blood brain barrier technologies market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe blood brain barrier technologies market
- Obtain market revenue forecast for market by various segments from 2021-2028 in Europe region.
Europe Blood Brain Barrier Technologies Market Segmentation
Europe Blood Brain Barrier Technologies Market – By Technology
- Bispecific Antibody RMT Approach
- Trojan Horse Approach
- Increasing Permeability
- Passive Diffusion
- Other Non-Invasive BBB Technologies
Europe Blood Brain Barrier Technologies Market – By Application
- Alzheimer’s Disease
- Epilepsy
- Parkinson’s Disease
- Multiple Sclerosis
- Hunter’s Syndrome
- Brain Cancer
- Others
Europe Blood Brain Barrier Technologies Market – By Country
- U.K.
- Germany
- France
- Italy
- Spain
- Rest of Europe
Europe Blood Brain Barrier Technologies Market – Companies Mentioned
- Teva Pharmaceutical Industries Ltd.
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Pfizer, Inc.
- Johnson & Johnson Services, Inc.
- Fabre-Kramer Pharmaceuticals, Inc.
- Bioasis Technologies, Inc.
- Abliva AB.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Blood Brain Barrier Technologies Market – By Technology
1.3.2 Europe Blood Brain Barrier Technologies Market – By Application
1.3.3 Europe Blood Brain Barrier Technologies Market– By Country
2. Europe Blood Brain Barrier Technologies Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Blood Brain Barrier Technologies Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Experts Opinion
5. Europe Blood Brain Barrier Technologies Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Up-surging Prevalence of Neurological Disorders
5.1.2 Raising Geriatric Population and Rising Prevalence of Age-Associated Neurological Disorders
5.2 Market Restraints
5.2.1 Problems in Brain Medication Delivery
5.3 Market Opportunities
5.3.1 High Number of Product Approvals and Launches
5.4 Future Trends
5.4.1 Scaling Demand of Nanoparticles for Brain Drug Delivery
5.5 Impact Analysis
6. Europe Blood Brain Barrier Technologies – Market Analysis
6.1 Europe Blood Brain Barrier Technologies Market Revenue Forecast and Analysis
7. Europe Blood Brain Barrier Technologies Market Analysis – by Technology
7.1 Overview
7.2 Blood Brain Barrier Technologies Market, by Technology 2021 & 2028 (%)
7.3 Bispecific Antibody RMT Approach
7.3.1 Overview
7.3.2 Bispecific Antibody RMT Approach: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Trojan Horse Approach
7.4.1 Overview
7.4.2 Trojan Horse Approach: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Increasing Permeability
7.5.1 Overview
7.5.2 Increasing Permeability: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Passive Diffusion
7.6.1 Overview
7.6.2 Passive Diffusion: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
7.7 Other Non-Invasive BBB Technologies
7.7.1 Overview
7.7.2 Other Non-Invasive BBB Technologies: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
8. Europe Blood Brain Barrier Technologies Market Analysis – By Application
8.1 Overview
8.2 Blood Brain Barrier Technologies Market, by Application 2021 & 2028 (%)
8.3 Alzheimer’s Disease
8.3.1 Overview
8.3.2 Alzheimer’s Disease: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Epilepsy
8.4.1 Overview
8.4.2 Epilepsy: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Parkinson’s Disease
8.5.1 Overview
8.5.2 Parkinson’s Disease: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Multiple Sclerosis
8.6.1 Overview
8.6.2 Multiple Sclerosis: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Hunter’s Syndrome
8.7.1 Overview
8.7.2 Hunter’s Syndrome: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
8.8 Brain Cancer
8.8.1 Overview
8.8.2 Brain Cancer: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
8.9 Others
8.9.1 Overview
8.9.2 Others: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
9. Europe Blood Brain Barrier Technologies Market – Country Analysis
9.1 Overview
9.1.1 Europe: Blood Brain Barrier Technologies Market, by Country, 2021 & 2028(%)
9.1.1.1 Germany: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.1.1 Germany: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.1.2 Germany: Blood Brain Barrier Technologies Market, by Technology, 2019–2028 (USD Million)
9.1.1.1.3 Germany: Blood Brain Barrier Technologies Market, by Application, 2019–2028 (USD Million)
9.1.1.2 France: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.2.1 France: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.2.2 France: Blood Brain Barrier Technologies Market, by Technology, 2019–2028 (USD Million)
9.1.1.2.3 France: Blood Brain Barrier Technologies Market, by Application, 2019–2028 (USD Million)
9.1.1.3 UK: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.3.1 UK: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.3.2 UK: Blood Brain Barrier Technologies Market, by Technology, 2019–2028 (USD Million)
9.1.1.3.3 UK: Blood Brain Barrier Technologies Market, by Application, 2019–2028 (USD Million)
9.1.1.4 Italy: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.4.1 Italy: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.4.2 Italy: Blood Brain Barrier Technologies Market, by Technology, 2019–2028 (USD Million)
9.1.1.4.3 Italy: Blood Brain Barrier Technologies Market, by Application, 2019–2028 (USD Million)
9.1.1.5 Spain: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.5.1 Spain: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.5.2 Spain: Blood Brain Barrier Technologies Market, by Technology, 2019–2028 (USD Million)
9.1.1.5.3 Spain: Blood Brain Barrier Technologies Market, by Application, 2019–2028 (USD Million)
9.1.1.6 Rest of Europe: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.6.1 Rest of Europe: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.6.2 Rest of Europe: Blood Brain Barrier Technologies Market, by Technology, 2019–2028 (USD Million)
9.1.1.6.3 Rest of Europe: Blood Brain Barrier Technologies Market, by Application, 2019–2028 (USD Million)
10. Impact Of COVID-19 Pandemic on Europe Blood Brain Barrier Technologies Market
10.1 Impact Assessment of COVID-19 Pandemic
11. Europe Blood Brain Barrier Technologies Market– Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 Teva Pharmaceutical Industries Ltd.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 F. Hoffmann-La Roche Ltd.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Eli Lilly and Company
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Bristol-Myers Squibb Company
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Pfizer, Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Johnson and Johnson Services, Inc.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Fabre-Kramer Pharmaceuticals, Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Bioasis Technologies, Inc.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Abliva AB.
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe Blood Brain Barrier Technologies Market – Revenue, and Forecast to 2028 (US$ Million)
Table 2. Germany: Blood Brain Barrier Technologies Market, by Technology – Revenue and Forecast to 2028 (USD Million)
Table 3. Germany: Blood Brain Barrier Technologies Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 4. France: Blood Brain Barrier Technologies Market, by Technology – Revenue and Forecast to 2028 (USD Million)
Table 5. France: Blood Brain Barrier Technologies Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 6. UK: Blood Brain Barrier Technologies Market, by Technology – Revenue and Forecast to 2028 (USD Million)
Table 7. UK: Blood Brain Barrier Technologies Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 8. Italy: Blood Brain Barrier Technologies Market, by Technology – Revenue and Forecast to 2028 (USD Million)
Table 9. Italy: Blood Brain Barrier Technologies Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 10. Spain: Blood Brain Barrier Technologies Market, by Technology – Revenue and Forecast to 2028 (USD Million)
Table 11. Spain: Blood Brain Barrier Technologies Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 12. Rest of Europe: Blood Brain Barrier Technologies Market, by Technology – Revenue and Forecast to 2028 (USD Million)
Table 13. Rest of Europe: Blood Brain Barrier Technologies Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 14. Organic Developments Done By Companies
Table 15. Inorganic Developments Done By Companies
Table 16. Glossary of Terms, Blood Brain Barrier Technologies Market
LIST OF FIGURES
Figure 1. Europe Blood Brain Barrier Technologies Market Segmentation
Figure 2. Europe Blood Brain Barrier Technologies Market Segmentation, By Country
Figure 3. Europe Blood Brain Barrier Technologies Market Overview
Figure 4. Increasing Permeability Segment Held the Largest Share by Technology in Blood Brain Barrier Technologies Market
Figure 5. U.K. to Show Significant Growth During Forecast Period
Figure 6. Europe Blood Brain Barrier Technologies Market, Industry Landscape
Figure 7. Europe and PEST Analysis
Figure 8. Europe Blood Brain Barrier Technologies Market– Revenue Forecast and Analysis – 2021 - 2028
Figure 9. Blood Brain Barrier Technologies Market, by Technology 2021 & 2028 (%)
Figure 10. Bispecific Antibody RMT Approach: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 11. Trojan Horse Approach: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Increasing Permeability: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Passive Diffusion: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Other Non-Invasive BBB Technologies: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Blood Brain Barrier Technologies Market, by Application 2021 & 2028 (%)
Figure 16. Alzheimer’s Disease: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Epilepsy: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Parkinson’s Disease: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Multiple Sclerosis: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Hunter’s Syndrome: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Brain Cancer: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Others: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Europe: Blood Brain Barrier Technologies Market, by Key Country – Revenue (2021) (USD Million)
Figure 24. Europe: Blood Brain Barrier Technologies Market, by Country, 2021 & 2028 (%)
Figure 25. Germany: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
Figure 26. France: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
Figure 27. UK: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
Figure 28. Italy: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
Figure 29. Spain: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
Figure 30. Rest of Europe: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
Figure 31. Impact of COVID-19 Pandemic in European Country Markets
- Teva Pharmaceutical Industries Ltd.
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Pfizer, Inc.
- Johnson & Johnson Services, Inc.
- Fabre-Kramer Pharmaceuticals, Inc.
- Bioasis Technologies, Inc.
- Abliva AB.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe blood brain barrier technologies market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Europe blood brain barrier technologies market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the blood brain barrier technologies market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution